-transparent.png){kind=logo}
37 evaluable patients with relapsed head and neck cancer received as treatment Cisplatin alone (18 patients) or Cisplatin + Adriamycin (19 patients). Both regimens consisted of three-weeks-interval courses. Cisplatin was administered at a dose of 100 mg/m2 as an i.v. infusion with prehydration, posthydration, mannitol and furosemide. Cisplatin + Adriamycin combination was administered at doses of 50 mg/m2 Cisplatin and 50 mg/m2 Adriamycin, both drugs the same day. Clinical toxicity was mild with both regimens. Overall hematologic toxicity was moderate but it was severe with regard to red cells. Some cases of renal toxicity were observed with Cisplatin regimen while no case was noticed with Cisplatin + Adriamycin combination. An overall response rate of 44% (4 CR + 4 PR) was achieved with Cisplatin protocol. The mean duration of response was 5,5 months. An overall response rate of 53% (3 CR + 7 PR) was achieved with Cisplatin + Adriamycin protocol. The mean duration of response was 2,75 months.
A Villar, and
B Farrus, and
P Giner, and
E Sedano, and
J Serradell, and
M de Caralt
June 2007,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Villar, and
B Farrus, and
P Giner, and
E Sedano, and
J Serradell, and
M de Caralt
May 1985,
Cancer,
A Villar, and
B Farrus, and
P Giner, and
E Sedano, and
J Serradell, and
M de Caralt
October 2007,
The New England journal of medicine,
A Villar, and
B Farrus, and
P Giner, and
E Sedano, and
J Serradell, and
M de Caralt
January 1977,
Tumori,
A Villar, and
B Farrus, and
P Giner, and
E Sedano, and
J Serradell, and
M de Caralt
January 1998,
Clinical oncology (Royal College of Radiologists (Great Britain)),
A Villar, and
B Farrus, and
P Giner, and
E Sedano, and
J Serradell, and
M de Caralt
June 1983,
Cancer treatment reports,
A Villar, and
B Farrus, and
P Giner, and
E Sedano, and
J Serradell, and
M de Caralt
February 2020,
JAMA otolaryngology-- head & neck surgery,
A Villar, and
B Farrus, and
P Giner, and
E Sedano, and
J Serradell, and
M de Caralt
May 2023,
Anticancer research,
A Villar, and
B Farrus, and
P Giner, and
E Sedano, and
J Serradell, and
M de Caralt
October 2012,
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
A Villar, and
B Farrus, and
P Giner, and
E Sedano, and
J Serradell, and
M de Caralt
February 2004,
Head & neck,
